Acadia Pharmaceuticals Inc (ACAD) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Acadia Pharmaceuticals Inc   (NASDAQ: ACAD)


Acadia Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Acadia Pharmaceuticals Inc's ROI in the third quarter of 2026?
Acadia Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 26.89 % in its third quarter of 2026, this is above ACAD's average return on investment of -35.06%.
Acadia Pharmaceuticals Inc invested over the 12 months ending in its third quarter of 2026 $1,347 million

ROI fell compared to the second quarter of 2026, despite the net income growth of 69.92% from the second quarter of 2026.

Within the Healthcare sector 37 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 151, from total ROI ranking in the second quarter of 2026 at 160.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 54.29 % 55.52 % 55.9 % 56.14 % 56.73 %
Y / Y Net Income Change TTM 38.69 % 71.27 % 92.15 % 121.52 % 697.11 %
Investment (TTM) in Millions 1,462 1,381 1,300 1,246 974
Return On Investment (TTM) 26.89 % 31.05 % 34.03 % 39.64 % 29.91 %
ACAD's Overall Ranking # 151 # 160 # 0 # 174 #
Seq. Investment Change TTM 9.95 % 11.01 % 11.91 % 12.96 % 10.83 %
Seq. Net Income Change TTM -4.8 % 1.29 % -3.93 % 49.71 % 17.56 %
Net Income (TTM) in Millions 362 380 376 391 261

ACAD Company Profile >> Back to ACAD Roi Comparisons >> See Annual ACAD Return On Investment



Return On Investment ACAD's Ranking
Within: No.
Industry # 21
Sector # 38
Overall # 151

Return On Investment Statistics
High Average Low
39.64 %
-35.06 %
-98.15 %
(Dec 31 2025)   (Sep 30 2012)



  News about Acadia Pharmaceuticals Inc Return on Investment ROI

Acadia Pharmaceuticals Leading the Charge in Rett Syndrome Treatment and Financial Performance,

October 16, 2024

Acadia Pharmaceuticals: Pioneering Advances in Rett Syndrome Treatment Amid Financial GrowthAcadia Pharmaceuticals Inc. a biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, has made significant strides in both clinical achievements and financial performance. Recently, the company announced that Health Canada granted marketing authorization for DAYBUE (trofinetide) for the treatment of Rett syndrome, making it the first and only drug approved in Canada specifically for this rare neurodevelopmental disorder. This approval, achieved through the Priority Review process, underscores Acadia s commitment to addressing unmet medical needs in complex conditions affecting both adult and pediatric patients aged two years and older.Rett syndrome is a genetic condition primarily affecting girls and is characterized by normal early development followed by a loss of acquired skills. This condition results in various challenges, including difficulties with speech, movement, and cognitive function. With the approval of DAYBUE, Acadia Pharmaceuticals not only provides a potential treatment option for patients and their families but also demonstrates the importance of developing targeted therapies for rare diseases.





Financial Statements
Acadia Pharmaceuticals Inc's III. Quarter Investments $ 1,462 Millions ACAD's Balance sheet
Acadia Pharmaceuticals Inc's III. Quarter Income $ 54 Millions Quarterly ACAD's Income Statement
ACAD's Income by Division See ACAD's Income by Division


ACAD Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,287 793 495 462 604
Y / Y Investment Growth 62.33 % 60.28 % 7.04 % -23.49 % -10.73 %
Net Income in Millions 391 226 -61 -216 -168
Y / Y Net Income Growth 72.66 % - - - -
Annual Return On Investment 30.38 % 28.56 % -12.39 % -46.73 % -27.79 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 30.38 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ACAD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ACAD's Competitors
Subscribers only: Roi for Acadia Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ACAD's Customers

Other Ratios
ACAD's Roa ACAD's Inventory Turnover Ratio ACAD's Growth Rates ACAD's Dividend Statistics
ACAD's Profitability Ratios ACAD's Asset Turnover Ratio ACAD's Dividend Growth
ACAD's Roe ACAD's Valuation Ratios ACAD's Financial Strength Ratios ACAD's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %

Date modified: 2026-11-09T06:44:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.